Michael Storek

814 total citations
32 papers, 451 citations indexed

About

Michael Storek is a scholar working on Hematology, Immunology and Physiology. According to data from OpenAlex, Michael Storek has authored 32 papers receiving a total of 451 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 17 papers in Immunology and 9 papers in Physiology. Recurrent topics in Michael Storek's work include Blood groups and transfusion (15 papers), Complement system in diseases (13 papers) and Erythrocyte Function and Pathophysiology (9 papers). Michael Storek is often cited by papers focused on Blood groups and transfusion (15 papers), Complement system in diseases (13 papers) and Erythrocyte Function and Pathophysiology (9 papers). Michael Storek collaborates with scholars based in United States, United Kingdom and France. Michael Storek's co-authors include V. Michael Holers, Ante S. Lundberg, Masha Fridkis‐Hareli, Antonio M. Risitano, Christopher Horvath, István Mazsaroff, Kamil Kuča, Gregory L. Verdine, Ilene C. Weitz and Josephine M. I. Vos and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Nature Biotechnology.

In The Last Decade

Michael Storek

31 papers receiving 440 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Storek United States 12 222 155 86 78 66 32 451
Margot Revel France 8 262 1.2× 58 0.4× 122 1.4× 25 0.3× 27 0.4× 15 423
Tsukio Masegi Japan 11 111 0.5× 58 0.4× 326 3.8× 25 0.3× 12 0.2× 19 575
Amanda J. Bradley Canada 10 127 0.6× 178 1.1× 168 2.0× 123 1.6× 7 0.1× 13 497
Tomio Yamazaki Japan 17 75 0.3× 466 3.0× 163 1.9× 34 0.4× 6 0.1× 44 761
Hege Lynum Pedersen Norway 11 224 1.0× 11 0.1× 187 2.2× 17 0.2× 33 0.5× 21 419
Agata Nowak Poland 12 112 0.5× 210 1.4× 108 1.3× 17 0.2× 12 0.2× 23 423
Colin A. Kretz Canada 16 102 0.5× 353 2.3× 200 2.3× 13 0.2× 8 0.1× 33 642
Klaus Mayer Germany 13 104 0.5× 72 0.5× 154 1.8× 7 0.1× 5 0.1× 31 438
Kari L. Murad United States 8 64 0.3× 232 1.5× 143 1.7× 238 3.1× 6 0.1× 9 630
Lori Ann Cox United States 11 145 0.7× 40 0.3× 93 1.1× 15 0.2× 5 0.1× 17 650

Countries citing papers authored by Michael Storek

Since Specialization
Citations

This map shows the geographic impact of Michael Storek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Storek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Storek more than expected).

Fields of papers citing papers by Michael Storek

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Storek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Storek. The network helps show where Michael Storek may publish in the future.

Co-authorship network of co-authors of Michael Storek

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Storek. A scholar is included among the top collaborators of Michael Storek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Storek. Michael Storek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ho, Hsi-en, Lin Radigan, Jingjing Qi, et al.. (2025). Bruton tyrosine kinase modulates systemic immune activation to bacterial translocation in primary antibody deficiencies. Journal of Allergy and Clinical Immunology. 156(6). 1693–1705.e5.
2.
Nissinen, Liisa, et al.. (2024). C1s targeting antibodies inhibit the growth of cutaneous squamous carcinoma cells. Scientific Reports. 14(1). 13465–13465. 5 indexed citations
3.
Röth, Alexander, Sigbjørn Berentsen, Wilma Barcellini, et al.. (2024). Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B. EClinicalMedicine. 74. 102733–102733. 5 indexed citations
4.
Daak, Ahmed, David R. Light, Fuad Abdulla, et al.. (2024). Bruton Tyrosine Kinase Inhibitor Rilzabrutinib Reduces Vaso-Occlusion and Markers of Inflammation and Adhesion in Transgenic Mice with Sickle Cell Disease. Blood. 144(Supplement 1). 2482–2482. 1 indexed citations
5.
Rajagopal, Vaishnavi, Nina C. Leksa, Ronald D. Gorham, et al.. (2023). SAR443809: a selective inhibitor of the complement alternative pathway, targeting complement factor Bb. Blood Advances. 7(16). 4258–4268. 5 indexed citations
6.
7.
Hussain, Sami, Kate Markham, Tony Byun, et al.. (2023). Anti-C1s humanized monoclonal antibody SAR445088: A classical pathway complement inhibitor specific for the active form of C1s. Clinical Immunology. 251. 109629–109629. 8 indexed citations
8.
Chow, Timothy Y., Pirouz Shamszad, Christopher Vinnard, et al.. (2023). First‐in‐human study with SAR445088: A novel selective classical complement pathway inhibitor. Clinical and Translational Science. 16(4). 673–685. 12 indexed citations
9.
D’Sa, Shirley, Josephine M. I. Vos, Wilma Barcellini, et al.. (2023). Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study. Blood. 143(8). 713–720. 12 indexed citations
10.
Röth, Alexander, Sigbjørn Berentsen, Wilma Barcellini, et al.. (2023). P1471: SUSTAINED EFFICACY OF SUTIMLIMAB, A COMPLEMENT C1S INHIBITOR, IN PATIENTS WITH COLD AGGLUTININ DISEASE: RESULTS FROM PART B OF THE PHASE 3 CADENZA STUDY. HemaSphere. 7(S3). e83270db–e83270db. 1 indexed citations
11.
Weitz, Ilene C., et al.. (2020). Inflammation and Fatigue in Patients with Cold Agglutinin Disease (CAD): Analysis from the Phase 3 Cardinal Study. Blood. 136(Supplement 1). 7–8. 8 indexed citations
12.
Marešová, Petra, et al.. (2020). New Regulations on Medical Devices in Europe: Are They an Opportunity for Growth?. Administrative Sciences. 10(1). 16–16. 20 indexed citations
13.
14.
Clinch, Keith, Rachel Dixon, Graeme J. Gainsford, et al.. (2013). Synthesis of Cyclic Pyranopterin Monophosphate, a Biosynthetic Intermediate in the Molybdenum Cofactor Pathway. Journal of Medicinal Chemistry. 56(4). 1730–1738. 24 indexed citations
15.
Li, Keying, Jayesh Gor, V. Michael Holers, Michael Storek, & Stephen J. Perkins. (2012). Solution Structure of TT30, a Novel Complement Therapeutic Agent, Provides Insight into Its Joint Binding to Complement C3b and C3d. Journal of Molecular Biology. 418(3-4). 248–263. 8 indexed citations
16.
Storek, Michael, Kendra A. Young, James M. Kovacs, et al.. (2010). Delineation of the Complement Receptor Type 2–C3d Complex by Site-Directed Mutagenesis and Molecular Docking. Journal of Molecular Biology. 404(4). 697–710. 15 indexed citations
17.
D’Ordine, Robert L., T.J. Rydel, Michael Storek, et al.. (2009). Dicamba Monooxygenase: Structural Insights into a Dynamic Rieske Oxygenase that Catalyzes an Exocyclic Monooxygenation. Journal of Molecular Biology. 392(2). 481–497. 39 indexed citations
18.
Mamluk, Roni, et al.. (2006). The type 1 repeat peptide ABT510 induces apoptosis of brain microvascular endothelial cells and inhibits glioblastoma tumor growth in vivo. Cancer Research. 66. 54–54. 1 indexed citations
19.
Mamluk, Roni, Irvith M. Carvajal, Steve G. Kovats, et al.. (2005). Preclinical development of a potent VEGFR-2 antagonist based on a novel protein scaffold (AdNectin). Cancer Research. 65. 714–715. 1 indexed citations
20.
Storek, Michael, Alexander Ernst, & Gregory L. Verdine. (2002). High-resolution footprinting of sequence-specific protein–DNA contacts. Nature Biotechnology. 20(2). 183–186. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Margot Revel Breakdown of academic impact, for papers by Tsukio Masegi Breakdown of academic impact, for papers by Amanda J. Bradley Breakdown of academic impact, for papers by Tomio Yamazaki Breakdown of academic impact, for papers by Hege Lynum Pedersen Breakdown of academic impact, for papers by Agata Nowak Breakdown of academic impact, for papers by Colin A. Kretz Breakdown of academic impact, for papers by Klaus Mayer Breakdown of academic impact, for papers by Kari L. Murad Breakdown of academic impact, for papers by Lori Ann Cox
Rankless by CCL
2026